Skip to main content
Clinical Trials/JPRN-UMIN000000947
JPRN-UMIN000000947
Unknown
未知

Reversal of diabetes and prevention of arteriosclerosis in type 2 diabetic patients with oral antidiabetic agents - Pioglitazone and Sulfonylurea Remission from T2DM development and anti-atherosclerosis in Japan : PREVENT-J

PREVENT-J Study Steering Committee0 sites500 target enrollmentDecember 14, 2007

Overview

Phase
未知
Intervention
Not specified
Conditions
Type2 Diabetes Mellitus
Sponsor
PREVENT-J Study Steering Committee
Enrollment
500
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 14, 2007
End Date
December 1, 2011
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
PREVENT-J Study Steering Committee

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \-Heart failure or history of heart failure. \-EF of less than 40%. \-History of adverse reactions to a thiazolidine derivative or concerns about safety. \-Severe hepatic dysfunction. \-Severe renal dysfunction. \-History of cardiovascular disease. \-Current treatment with a sulfonylurea drug. \-Current treatment with a thiazolidine derivative. \-Current treatment with insulin. \-Those whom the principle investigator or other investigators consider unsuitable.

Outcomes

Primary Outcomes

Not specified

Similar Trials